Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
Patients who completed the study TVP-1012/232 are eligible to enter the extension study to
continue their rasagiline therapy for their Parkinson's disease (PD). During this study the
patient's safety, tolerability of rasagiline, and effectiveness of this therapy will be
monitored.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries